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The immune system is highly controlled and fine-tuned by glycosylation, through the
addition of a diversity of carbohydrates structures (glycans) to virtually all immune cell
receptors. Despite a relative backlog in understanding the importance of glycans in
the immune system, due to its inherent complexity, remarkable findings have been
highlighting the essential contributions of glycosylation in the regulation of both innate
and adaptive immune responses with important implications in the pathogenesis of
major diseases such as autoimmunity and cancer. Glycans are implicated in fundamental
cellular and molecular processes that regulate both stimulatory and inhibitory immune
pathways. Besides being actively involved in pathogen recognition through interaction
with glycan-binding proteins (such as C-type lectins), glycans have been also shown to
regulate key pathophysiological steps within T cell biology such as T cell development
and thymocyte selection; T cell activity and signaling as well as T cell differentiation and
proliferation. These effects of glycans in T cells functions highlight their importance as
determinants of either self-tolerance or T cell hyper-responsiveness which ultimately
might be implicated in the creation of tolerogenic pathways in cancer or loss of
immunological tolerance in autoimmunity. This review discusses how specific glycans
(with a focus on N-linked glycans) act as regulators of T cell biology and their implications
in disease.
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INTRODUCTION
The immune system is highly regulated by a series of stimulatory and inhibitory pathways that are
crucial to maintain a healthy and balanced system. Disruption of the control of this immunological
balance can result in abnormal stimulatory signals associated with the loss of immune tolerance in
autoimmunity or in the creation of aberrant immunosuppressive networks that occur in cancer.
Accumulating evidences have been demonstrating the importance of glycans and glycans binding
proteins [including galectins (1, 2), C-type lectins (3), and sialic acid-binding immunoglobulin-type
lectins (siglecs) (4, 5)] in the regulation of both innate and adaptive immune responses. In fact, all
cells are covered with a dense coat of glycans that constitute a major molecular interface between
cells and their environment. The diversity of glycans presentation at cell surface is enormous,
encoding a myriad of important biological information that remains to be fully characterized.
Glycosylation is the enzymatic process responsible for the attachment of glycans (carbohydrates) to
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proteins or lipids (predominantly via nitrogen (N) and oxygen
(O) linkages), a process that occurs in the Endoplasmic
Reticulum/Golgi compartment of essentially all cells being
mediated by the coordinated action of a portfolio of different
glycosyltransferases and glycosidases enzymes (6). The proper
development and function of the immune system relies both on
the dynamic regulation of the expression of glycan-structures
and glycan-binding proteins, and the interactions between
them (7). This review discusses the role of glycans (with a
focus on N-linked glycans) on T cells biology and function,
including T cell development, activation, differentiation, and
signaling. This dynamic interplay between glycans and T cells
activity controlling both auto-reactivity and self-tolerance will be
presented and discussed (Figure 1).
GLYCANS IN T CELL DEVELOPMENT AND
THYMUS SELECTION
T cells are developed in the thymus where a microenvironment
is set, which enables the selection of T cell receptors (TCRs)
to generate a diverse repertoire of potential antigen recognition
(8). Lymphoid progenitors from the bone marrow enter into the
cortical tissue of the thymus, where they start to expand and
develop (9, 10). Despite the fact that the role of glycosylation in
T cell development and thymus selections still remains to be fully
understood, some important findings highlight the relevance of
glycans in this process (Figure 2).
Role of Glycans in Thymus Seeding and T
Cell Lineage Commitment
The initial step of T cell development, the trafficking of
thymus-seeding progenitors (TSPs) to the thymus, is an active
process that relies on the expression of P-selectin in the
thymic epithelium and its partner, P-selectin glycoprotein
ligand-1 (PSGL-1), expressed by circulating TSPs-derived from
the bone marrow (11). The expression and post-translational
modifications of PSGL-1 are regulated in bone marrow
progenitors. The deficiency of α1,3 fucosylation on PSGL-1,
required for its binding to P-selectin, was shown to be associated
with the impairment of TSPs homing into the thymus (12).
Once TSPs enter the thymus, they develop into early thymocyte
progenitors (ETPs), a subset of the CD4−CD8− double negative 1
(DN1) population, which give rise to multiple lymphoid lineages
(8). The conserved Notch signaling pathway is responsible for
the commitment of DN1 thymocytes to the T cell lineage
(13). The glycosylation profile of Notch receptors (and ligands)
was shown to regulate Notch-dependent intracellular signal
transduction. The lunatic, manic, and radical Fringe are the
glycosyltransferases that modify Notch receptors by transferring
N-acetylglucosamine (GlcNAc) to O-linked fucose glycans of
epidermal growth factor-like (EGF-like) repeats, present in the
extracellular domain of Notch, and described to regulate its cell-
surface signaling and function (14, 15). Loss of the three Fringe
glycosyltransferases leads to a reduced binding of Notch to Delta-
like ligands (DLL), namely DLL4, altering the frequencies of
several T cell subsets in the thymus (16). The first indication
that Fringe-mediated Notch glycosylation was involved in T cell
development was shown when the lunatic Fringe gene, Lfng,
was misexpressed under a lck-proximal promoter (17). This
alteration of the Notch glycosylation profile (lack of GlcNAc
in the EGF-like repeats) resulted in a large B cell population
developed from lymphoid progenitors in the thymus. In fact,
further work showed that Lfng is poorly expressed in CD4+CD8+
double positive (DP) thymocytes, but when ectopically expressed
in that population (under lck-proximal promoter), led to an
increased binding of Notch to its ligands on stromal cells,
blocking DN development, and enabling B cell differentiation
(18). These studies also revealed that changes in the glycosylation
of Notch across T cell development also impacts on its signaling
pathway. At DN stages, the reactions that drive development
are dependent on Notch interactions with DLLs, which exist
at functionally limiting concentrations. The high levels of Lfng
expression in DNs facilitate Notch interactions with DLLs and
the dramatic downregulation of Lfng in DPs coincides with
Notch-independent reactions of T cell development. The final
commitment to the T cell lineage occurs at the DN3 stage, where
a recombination-activating genes (RAG)-mediated productive
rearrangement of the Tcrb leads to the expression of the ß chain
of the TCR (TCRß) and the formation of a pre-TCR signaling
complex (13, 19).
Role of Glycans in Thymocyte ß Selection
Together with Notch and Interleukin (IL)-7, the pre-TCR
signaling initiates ß-selection, by inducing the downregulation of
the RAG complex expression (Rag1 and Rag2) in quiescent DN3
(DN3a), becoming large cycling DN3 thymocytes (DN3b), which
differentiate into DN4 cells. A deficient pre-TCR signaling in lck-
null cells is rescued by Lfng overexpression, but not in a Rag2−/−
background, indicating a pre-TCR dependency for development
(20). Upon ß-selection, it was recently demonstrated that DN4
cells upregulate glucose and glutamine metabolites that enter
into the hexosamine pathway, increasing the production of
UDP-GlcNAc, which is needed to undergo clonal expansion
(8, 21). The UDP-GlcNAc is also the substrate of the O-
GlcNAc transferase (OGT) in the process of O-GlcNAcylation
of intracellular proteins on serine and threonine residues (22).
Recent evidences showed that O-GlcNAcylation regulates the
process of T cell development (23). Using a conditional knockout
mouse model of OGT in the DN stage, it was shown a reduced
population of DPs, indicating either a deficiency on ß-selection
or in clonal expansion of DN4s. The absence of OGT appeared
not to impact self-renewal of DNs, or their differentiation into
DPs, but to promote the failure of the clonal expansion of
DN4, in response to Notch ligands. A feedback mechanism was
proposed in which the metabolic changes (the shift to glycolysis)
that support the DN-to-DP stage of thymocyte differentiation,
controlled by Notch, induces c-Myc expression, which in turn
controls the rate of T cell nutrient uptake as well as the expression
of OGT and consequently the abundance of O-GlcNAc (15). The
O-GlcNAcylation of c-Myc was also shown to increase its stability
(24), further contributing to the feedback loop.
In the stage of post-β selected DN4 thymocytes, it was
seen a 10-fold increase in expression of ST6 β-Galactoside
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FIGURE 1 | Glycans as a major connective chain that controls T cell response in either a tolerogenic or immunostimulatory scenario. Glycosylation appears to be
central in regulating several steps of a T cell’s life. During T cell development, different population of T cells (ETP, early thymocyte progenitor; DN1, 2, 3, and 4, double
negative; DP, double positive; SP, single positive) display specific glycosylation patterns. The normal glycosylation of SP population results in an educated T cell
function. However, by genetic, environmental or metabolic constrains, T cell glycosylation can be compromised re-directing immune system toward an
immunostimulatory or tolerogenic response. Glycans are proposed here as key players in immune-unbalanced diseases, such as autoimmunity and cancer.
α2,6-Sialyltransferase 1 (ST6Gal I) when comparing to the
DN3 population, which resulted in an increase in α2,6-linked
sialic acid (25). Accordingly, in ST6Gal1 deficient mice, the
DN populations were decreased, beginning at the DN1 subset.
Microarray data showed a downregulation of CD96 (receptor
molecule of nectin-1, that plays a putative role in cell migration)
in the DN2 and DN3 populations in the ST6Gal1 deficiency
background, and a disruption of thymopoiesis in these mice was
proposed. Moreover, ST3 β-Galactoside α2,3-Sialyltransferase
1 (ST3Gal I) expression is decreased in most DN and in all
DP, only increasing in single-positive (SP) thymocytes (26). In
ST3Gal1−/− mice, the TCR repertoire was significantly altered,
indicating a role for sialylation in thymocyte selection (27).
Role of Glycans in Positive and Negative
Selection in the Thymus
The ß-selected DN4 cells undergo rapid self-renewal, giving
rise to a clonally expanded population, that differentiate into
DP CD4+CD8+ thymocytes (8). In this developmental stage,
mature TCRαß receptors are formed (28) and the expression
of the co-receptors CD4 and CD8 confer a MHC class II and
class I restriction of TCR activation, respectively. The newly
formed mature TCRs are then screened by thymic epithelial cells
(TECs) by the specificity and binding strength for the MHC
ligands presented. The next developmental process is named
positive selection, where the DP population is enriched for cells
that express an immunocompetent TCR (8, 29). The selected
DPs then commit to the SP CD4+ or CD8+ lineage and go
through a process called negative selection, which eliminates
autoreactive T cells (8, 29). The affinity of the correctly assembled
TCRαβ for the MHC-antigen complexes determines cell survival
and differentiation. Glycosylation modifications of the TCR
may provide an alternative mechanism to control positive and
negative selection by directly affecting the TCR-MHC-antigen
binding, TCR interaction with its co-receptors and the threshold
of activation (30), an issue that is far from being fully elucidated.
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FIGURE 2 | The hallmarks of glycans in T cell biology. N-glycans have a broad effect on the multiple T cell functions with impact both in autoreactivity and in immune
tolerance. Particularly, the complex branched N-glycans catalyzed by beta 1,6-N-acetylglucosaminyltransferase V (GnT-V) (encoded by MGAT5 gene) have been
demonstrated to control different T cells functions by targeting different T cells receptors (such as TCR, CD25, and CD4) and therefore regulating T cell proliferation, T
cell differentiation, T cell signaling as well as the production of inflammatory cytokines. Alterations on GnT-V activity but also in alpha-mannosidase II (α-MII) as well as
in N-acetylglucosaminyltransferase I (GnT-I, MGAT1 gene) and II (GnT-II, MGAT2 gene) activity were shown to compromise T cell homeostasis being associated with
the development of several autoimmune disorders in humans and mouse models (such as EAE, IBD, SLE, TID). The FUT8-mediated core fucosylation of TCR was
associated with hyperactivation of CD4+ T cells (T cells autoreactivity) whereas the modification of the co-inhibitory receptors (CTLA-4 and PD-1) by FUT8-mediated
core fucose results in immune tolerance. The T cell development and T cell self-renewal are controlled by GnT-I-mediated glycosylation and by O-GlcNAcylation
through OGT (O-GlcNAc transferase), respectively.
The subunits of the TCRαβ contain at least 7 potential sites for
N-linked glycosylation and the TCR-CD3 complex is estimated
to have 12N-glycan addition sites that contribute to TCR folding
and functions (31, 32). Indeed, selective removal of conserved N-
glycosylation sites of the constant regions of the TCR, enhanced
its functional avidity (the sensitivity of the T cell response
to other cell which carries the respective MHC-peptide) (32).
However, whether N-glycosylation in the variable regions of
the TCR affect its selection remains to be addressed. Moreover,
low levels of sialylation in DPs are associated with binding to
Major Histocompatibility Complex (MHC) class I (common to
all nucleated cells) and the increased expression of sialic-acid
linkages on differentiated SP CD8+ thymic T cells was shown to
decrease the binding avidity of CD8 for MHC class I molecules,
which acts as a regulation for a TCR affinity dependent negative
selection (33).
Furthermore the deficiency of the Mgat5 gene, that encodes
for a Golgi branching enzyme N-acetylglucosaminyltransferase
V (GnT-V) was shown to markedly increases TCR clustering
and signaling at the immune synapse, resulting in a lower T
cell activation threshold and increased incidence of autoimmune
disease in vivo and in human (30). In a model of positive
selection, it was demonstrated that branching N-glycosylation
dynamically expands the affinity spectrum of positive selection
by differentially controlling both the lower and upper limits
of positively selected TCR-MHC-antigen interactions (34). The
intracellular domains of CD4 and CD8 co-receptors bind
Lck, enhancing TCR responses to low-affinity MHC-antigen
complexes when coupled to the TCR (35). Both co-receptors
have N-glycosylation sites and it was shown that the branching
deficiency in Mgat1f/fLck-Cre+ T cells resulted in decreased
surface expression of CD4 and CD8 receptors (34). The
lack of branched N-glycans in the same genetic background
also decreased TCR threshold signaling (30). These evidences
supported that branching N-glycans display an important role in
the maturation of DN cells and/or TCR selection.
Changes in the expression of O-linked glycans also impact
T cell development by modulating galectin binding. Galectin-1
was shown to induce apoptosis of immature thymocytes through
binding to core 2 O-glycans expressed in CD43 and CD45 (36).
In contrast, CD45 on mature thymocytes bears core 1 O-glycans
as well as N-glycans capped with α2,6-linked sialic acid, which
inhibits galectin-1 binding (36).
Overall, glycosylation appears to play a critical role in the
different stages of thymocyte development and in the generation
of an efficient immune system. Nevertheless, further research is
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needed in order to understand how glycans control each stage
of thymocytes development, differentiation and selection, which
might reveal novels insights on the influence of the glycome in
major diseases, such as autoimmunity and cancer.
GLYCANS IN THE REGULATION OF T CELL
ACTIVITY AND FUNCTIONS
The proper function of T lymphocytes is highly dependent on
their surface receptors, which in turn are highly mediated by
glycosylation. Although O-glycan structures have been shown to
play important roles on immune-associated molecules (37), the
prominent role of N-linked glycans is emphasized in this section
(Figure 2).
As previously mentioned, MHC I is expressed by almost all
nucleated cells and interacts with TCRs on CD8+ T cells; in
turn, MHC II is expressed by professional antigen presenting
cells (APCs) (dendritic cells - DC, macrophages, B cells and
TECs) and is recognized by CD4+ T cells (7, 38). More than
3 decades ago, it was demonstrated that blocking MHC1a
N-glycosylation, through acceptor site mutation, results in
significant increases in intracellular misfolded protein along
with decreases in cell surface expression (39). MHC II is
assembled by two glycoproteins, α and β chains. The α chain
contains N-linked high-mannose and complex glycans whereas
the β chain is only constituted by complex N-glycans (40).
In contrast to the role of MHC I, MHC II glycosylation was
shown to have a particular impact on the effective antigen
binding, as well as in the presentation of microbial carbohydrate
antigens, which consequently influences downstream T cell
responses. This was demonstrated by the depletion of the
Mgat2 gene, which compromisesN-glycan branching, decreasing
carbohydrate antigen presentation by MHC class II and leading
to loss of T cell stimulatory activity (41).
During TCR signal transduction, glycans play a key role
in stabilizing individual molecules in the complexes at the
immunological synapse and by protecting them from the action
of proteases during T cell engagement (31). Additionally, glycans
can also restrict nonspecific protein-protein interactions, like
aggregation of TCRs on the membrane, helping to orient
the interactions of the proteins in the central clusters (31).
Demetriou et al. demonstrated that β1,6-GlcNAc branched N-
glycans structures (catalyzed by GnT-V) regulate T cell activity,
namely in CD4+ T cells by increasing the threshold of T cell
activation, suppressing T cell growth and signaling (30, 42).
Moreover, core-fucosylation, which refers to fucose attached
to the innermost N-acetylglucosamine of N-linked glycans,
catalyzed by α1-6 fucosyltransferase (FUT8), was also shown to
affect T cell activity in immune mediated disorders (42, 43).
The T cell activity is also dependent on glycosylation
of co-receptors, such as the complex formation between
TCR and CD45. Galectin-3 is a key mediator of this
complex, by establishing a molecular lattice through
binding to polylactosamine structures in branched N-
glycans. Consequently, CD45 phosphatase activity induces
downregulation of T cell signaling, preventing T cell activation
(44). Furthermore, CD45 is alternatively spliced into five
different isoforms on human leukocytes (CD45ABC, CD45AB,
CD45BC, CD45B, and CD45RO) (45–47), all decorated with up
to 11 N-glycans in the membrane proximal region. Importantly,
all isoforms present different glycosylation profiles (48, 49), that
change during T cell differentiation and activation (50, 51), as
reviewed in (36). CD28 is another T cell surface glycoprotein
acting as a secondary signaling molecule of T cell activation.
Interestingly, nearly 50% of the molecular mass of CD28
is constituted by N-glycans (52). Previous studies reported
that N-glycosylation of human CD28 can negatively regulate
CD28-mediated T cell adhesion and co-stimulation, namely
the interaction between CD28/CD80. Mutation of all potential
N-linked glycosylation sites of CD28 as well as treatment of
Jurkat cells with inhibitors of N-glycosylation pathway resulted
in a defective CD28 glycosylation with enhancement of the
binding to CD80 expressed on APCs (52). The branching
N-glycosylation of CD25 receptor also modulates its cell surface
retention controlling T differentiation with impact in immune
tolerance. Recently, it was demonstrated that a decreased
UDP-GlcNAc and complex branching N-glycosylation induces
a decreased cell surface retention of CD25 and IL-2 signaling,
promoting a T helper (TH) 17 over induced regulatory T cell
(iTreg) differentiation (53) (Figure 2).
Importantly, the co-inhibitory receptors are likewise
modulated by N-glycosylation. One of the major negative
regulators of T cell response is the cytotoxic T-lymphocyte
protein 4 (CTLA-4), that comprises two N-glycosylation sites
described to modulate its cell surface retention on T cells and
thereby its affinity for CD80/CD28 on APCs (54–56). The
impact of N-glycosylation in the modulation of the inhibitory
functions of CTLA-4 and programmed cell death protein-1
(PD-1) is discussed in more detail in section “Glycans in
tolerogenic/immunosuppressive responses”. Nonetheless, other
co-inhibitory receptors like Lymphocyte-activation gene 3
(Lag-3), mucin-domain-containing molecule-3 (Tim-3), and
T cell immunoreceptor with Ig and ITIM domains (TIGIT)
may also undergo glycans-mediated regulation, as they exhibit
N-glycan-binding sites, however the role of glycans on these
molecules remains to be explored (57).
Taken together, N-glycosylation plays an instrumental role in
the regulation of T cell activation and functions by targeting not
only TCR but also its co- receptors (Figure 2).
GLYCANS AS MODULATORS OF
HYPER-REACTIVE/AUTOIMMUNE
RESPONSES
Autoimmunity is characterized by the loss of self-tolerance and
development of an autoreactive immune response toward the
individual’s own organism. Glycan motifs play a crucial role
in the determination of self/non-self antigens. Specific glycan
structures, expressed by microbial pathogens, are commonly
responsible for the primary activation of the innate immune
system; however, the mechanisms involved in the self/non-self
discrimination, mediated by glycans are far from being fully
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elucidated. Abnormal levels of branched N-glycans have been
associated with exacerbated immune responses inmurinemodels
(58). Particularly, the dysregulation of the N-glycosylation
pathway has been associated with autoimmune-like phenotypes.
The inability to synthetize β1,6-GlcNAc antennae, in Mgat5−/−
mice has been associated with an increased susceptibility to
immune-mediated disorders such as an increased delayed-type
hypersensitivity responses, as well as increased susceptibility to
develop experimental autoimmune encephalomyelitis (EAE) (30,
59) and severe forms of colitis (60). The lack of β1,6 branching
N-glycans favors TCR clustering, leading to a decrease of the
TCR threshold and consequently increased T cell activation
(30) associated with the hyperimmune response observed in
these mice (Figure 2). This hyperimmune phenotype is also due
to an abnormal formation of lattices between TCR-branched
glycosylation and galectins (61, 62). Accordingly, β3 GnT2-
deficient mice show T cell hypersensitivity due to the reduction
of polylactosamine on the N-glycans (ligands of galectins),
similarly to what is observed in Mgat5 deficient mice (30, 61).
Furthermore, absence of α-mannosidase II (which catalyses
the last hydrolysis of the α-mannose), was shown to result
in signs of glomerulonephritis, deposits of glomerular IgM
immunocomplexes and complement component 3 as well as high
levels of anti-nuclear antibodies (63, 64), which is consistent
with a Lupus-like syndrome (Figure 2). Taken together, these
evidences support the role of N-glycosylation in the perspective
of T cell biology.
The role ofN-glycans in antigen presentation and recognition
is still elusive, and in fact abnormal glycoantigen presentation
might also impact T cell activity. Abnormal accumulation
of high-mannose, paucimannose, and agalactosyl bi-antennary
glycans, have been detected in kidney tissue from MRL-lpr
mouse (a well-stablished murine model of SLE) (65). Moreover,
evidences have been showing that Mgat1f/fSyn1-Cre mice, with
Mgat1 deletion at the Synapsin I-expressing cells (abundant in
neural tissues), presented neurological defects, with high levels
of neuronal apoptosis and caspase 3 activation (66). These high
levels of apoptosis are observed in several autoimmune diseases,
which results in activation of immune system (67) (Figure 2).
Although highly unexplored, rare autoimmune diseases are
also associated with N-glycosylation dysfunctions. As example,
idiopathic inflammatory myopathies (IIM) are a group of
rare diseases of autoimmune nature, whose etiopathogenesis is
far from being totally understood (68). Muscle cells surface
is enriched with glycoproteins and several lines of evidence
provide support for a fundamental role of glycosylation in
muscle homeostasis and function (69, 70). Glucosamine (UDP-
N-Acetyl)-2-Epimerase/N-Acetylmannosamine Kinase (GNE)
genetic mutations (a gene that encodes N-acetylmannosamine
(ManNAc) kinase enzyme, responsible for the biosynthesis of
N-acetylneuraminic acid) results in hypo-sialylation of muscle
glycoproteins; the prophylactic supplementation with sialic
acid precursor (ManNAc) was shown to prevent the muscle
phenotype in mice with gene mutations that cause hereditary
inclusion-body myositis (hIBM), a muscle phenotype that
resembles one type of IIM (71). Altogether, these findings
highlight the importance of further studies addressing the role
of N-glycosylation in the perspective of neoautoantigens, since
autoantigens contain a significant amount of glycoantigens due
to the increased number of N-glycosylation sites comparing with
other proteins (72).
The Glycan binding proteins (GBPs) are expressed in the
APCs being characterized by a carbohydrate recognition domain
which specifically recognizes glycan structures present at the
cell surface receptors. This glycan-GBPs engagement results
in either an anti- or pro-inflammatory response (73). C-type
lectins, siglecs, and galectins are examples of GBPs, that are
instructors of immune responses (5, 73). As example, SIGN1R
(expressed by APCs and the analogous of the human dendritic
cell-specific ICAM-grabbing non-integrin - DC-SIGN) signaling
was shown to result in the expansion of IL-10-secreting Treg
cells, preventing the development of autoimmune diseases such
as EAE and type 1 diabetes (T1D) (74). Galectin-1 also plays
an important immune-regulatory role in EAE (75) as mice
deficient in galectin-1 (Lgals1−/−) have increased TH1 and TH17
responses being more susceptible to EAE when compared with
wild type mice (76). More recently, Galectin-1 was shown to
modulate the cytolytic activity of CD8+ T cell. The interaction
of Galectin-1 and Fas ligand seems to be responsible for the
retention of this glycoprotein at the surface of cytotoxic T
lymphocytes hampering the cytolytic ability of these cells (77).
Overall, GBPs-glycoprotein interaction is essential to instruct a T
cell—mediated immune response.
Notably, one of the first evidences addressing the relationship
between the dysregulation of N-glycosylation and human
autoimmunity was observed in multiple sclerosis (MS) patients.
During active, relapse or in very early stages of remission,
peripheral blood mononuclear cells from MS patients display a
significant decrease of the enzymatic activity of Golgi β1,6 N-
acetylglucosaminyltransferase (core 2 GlcNAc-T), compared to
healthy subjects (78). Moreover, MGAT5 polymorphisms were
associated withMS severity (79) together withMGAT1, IL2R, and
IL7R Single Nucleotide Polymorphisms (80–82). Additionally,
in Inflammatory Bowel Disease (IBD), it was also demonstrated
that lamina propria T lymphocytes from ulcerative colitis (UC)
patients exhibited a deficiency in β1,6-GlcNAc branching N-
glycans due to decreased levels of MGAT5 gene expression (83).
Importantly, low levels of branched N-glycans in lamina propria
early at diagnosis were shown to predict UC patients that will
fail the response to standard therapy, thus displaying a bad
disease course (84). The supplementation of intestinal T cells
from UC patients and mouse models with colitis with GlcNAc
promoted the enhancement of β1,6 branching N-glycans on T
cells, suppressing TCR signaling and reducing the production of
pro-inflammatory cytokines such as tumor necrosis factor alpha
(TNFα) and interferon gamma (IFNγ). Pre-clinical studies both
in IBD andMS demonstrated the immunomodulatory properties
of N-glycans in the control of T cell-mediated immune response
(60, 85), paving the way for the development of human clinical
trials, that are currently on going (53, 60). Less explored but
of utmost importance is the study of N-glycosylation profile
in rare autoimmune disorders, since its etiopathogenesis is still
very elusive. Glycosylation changes in muscle-associated human
disease have focused in muscular dystrophies (86) and congenital
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disorders of glycosylation (87). Recent studies have shown that
muscle cell surface glycosylation is finely regulated and subjected
to alterations under inflammatory conditions (88), pointing
to a possible interaction between muscle glycocalyx and the
extracellular milieu, which is particularly enriched in immune
cells and antibodies in IIM patients (89).
Overall, glycans are critical determinants in autoreactive
responses both by directly regulating T cell activity and also
through the creation of abnormal glycoantigens that may unleash
an autoreactive immune response.
GLYCANS IN
TOLEROGENIC/IMMUNOSUPPRESSIVE
RESPONSES
Recent studies have been highlighted that alterations on the
glycosylation pattern of T cells’ receptors, as well as the alterations
of the glycosylation profile of tumor cells (tumor glyco-code), are
implicated in the modulation of the immune response leading
to immunosuppressive pathways, known to occur in the tumor
microenvironment associated with tumor immunoescape (90).
Role of Glycans in the Modulation of
Inhibitory T Cell Receptors
PD-1, as already introduced, is a cell surface inhibitory T cell
receptor responsible for immune-inhibitory responses associated
with the so-called “T cell exhaustion” (91). The expression of
this cell surface receptor, as well as Tim-3, was described to be
positively regulated by the core fucosylation pathway, catalyzed
by FUT8 enzyme (92). The inhibition of core fucosylation
in PD-1 was demonstrated to lead to an anti-tumor immune
response mediated by T cells activation, being a new attractive
target for enhancing anti-tumor immunity in future clinical
settings (Figure 2). This was a pioneer study that supported
the importance of PD-1 post-translational modifications by
glycosylation on T cell-mediated immunosuppression (92).
Additionally, the glycosylation of programmed death ligand-1
(PD-L1), a PD-1 ligand, was described to have an important role
in its cellular stabilization. The interaction of non-glycosylated
PD-L1 with glycogen synthase kinase 3β (GSK3β), a key enzyme
on glycogenesis, leads to the degradation of this molecule (93). In
triple-negative breast cancer cells, it was further shown that the
β1,3-N-acetylglucosaminyl transferase (B3GNT3), involved in
the biosynthesis of poly-N-acetyllactosamine chains, is important
for the interaction between PD-1 and its ligand PD-L1 (94). The
use of an antibody targeting the glycosylated form of PD-L1
resulted in its degradation and internalization, with the blockage
of PD-L1/PD-1 interaction and consequently the inducement
of anti-tumor activity in triple-negative breast cancer in vitro
and in vivo models (94). In accordance, Tregs from healthy
humans and mice were shown to display an increased variability
on its N-glycosylation pattern when compared with CD4+ T
cells. The levels of the complex branched N-glycans were shown
to be correlated with the expression of proteins involved in
Treg suppressive functions, including PD-1, PD-L1, and also
other negative regulators of T cell response, namely CTLA-4
(95). In fact, the CTLA-4 protein, comprises multiple N- and
O-glycosylation sites known to modulate its retention at T cell
surface and consequently affecting its function (56). The TCR
activation is associated with an increased β1,6-GlcNAc branched
N-glycosylation of CTLA-4, which enhances CTLA-4 retention
at the T cell surface and thereby suppresses T cell activation
promoting immune tolerance (96) (Figure 2). Accordingly, the
presence of Thr17Ala polymorphism in human CTLA-4 was
shown to result in the reduction of the N-glycosylation sites
from one to two sites, which limited CTLA-4 retention at T
cell surface (80). Supplementations with GlcNAc and Vitamin D
promoted an enhancement of N-glycans branching expression,
increasing the cell surface retention of CTLA-4, culminating in
immunosuppression (80).
Glycans as Instructors of
Immunosuppressive Responses
Tumor cells aberrantly express different types of glycans
structures when compared with normal counterparts, such as an
increased sialylation, an expression of truncated glycans and an
overexpression of branched N-glycans (97). This alteration in
the cellular glycosylation profile governs several steps of tumor
development and progression, such as tumor cell dissociation,
proliferation, invasion, metastasis, angiogenesis, with recent
evidences pointing toward its effects in tumor immunoediting
and immunosurveillance (98). GBPs expressed on immune cells
are able to recognize altered glycan structures expressed at
tumor cell surfaces instructing either immunostimulatory or
immunoinhibitory responses.
The expression of sialylated glycans, such as Tn antigen
and Lewis antigens, aberrantly expressed in tumor cells,
were described to be recognized by DC-SIGN, expressed
by macrophages and immature DCs, which lead to
immunosuppression (99). The fucose residues present in Lewis
structures (Lewis x and Lewis y), attached to carcinoembryonic
antigen (CEA) (100), were described to trigger the upregulation
of the anti-inflammatory cytokines IL-10 and IL-27 by APCs
and the induction of TH2, follicular (THf), and Treg immune
responses (101, 102). Besides, antigen-containing liposomes
modified with DC-SIGN-binding Lewis b and x resulted
in glycans recognition and internalization through DCs
with consequent activation of CD4+ and CD8+ T cells
(103). Furthermore, macrophage galactose binding lectin
(MGL) was found to be able to recognize Tn antigen and N-
acetylgalactosamine (GalNAc) residues, resulting in an increased
recognition by Toll-like receptor 2, ultimately resulting in the
secretion of cytokines (IL-10 and TNF-α). (104). Its interaction
with terminal GalNAc residues on CD45 glycoprotein negatively
regulates TCR signaling, with consequent decrease of T cell
proliferation and increased T cell death (105). Moreover, by
blocking the tumor-infiltrated macrophages (responsible for
the high levels of IL-10), it was observed an effective CD8+
T cells response, highlighting the importance of combining
anti-tumor immune therapy with conventional chemotherapy
(106). Furthermore, it was recently demonstrated in chronic
infection that IL-10 induces the upregulation of the Mgat5
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gene increasing branched N-glycans on CD8+ T cells, which
in turn decreases T cell activity and allows viral persistence
(107). Despite the different context in which this hypothesis was
studied, Mgat5-mediated branching glycosylation can constitute
a potential mechanism by which IL-10 is suppressing CD8+T
cells in cancer.
In addition, sialylated glycans also play a role in
immunosuppression, mediated by siglecs, a family of lectin
receptors that predominantly exhibit immune-inhibitory
functions. In in vitro and in vivo studies, the binding to
sialylated antigens by siglec-E expressed on DCs promoted
an increase of antigen-specific Treg response and a reduced
numbers of antigen-specific Teff cell response, associated
with tumor growth (108, 109). Indeed, the sialylated tumor
antigens, such as Sialyl-Tn (sTn) and Sialyl-T (sT) expressed in
mucins, namely MUC1, were associated with tumor immune
tolerance. The recognition of MUC1-ST by siglec-9 on tumor-
infiltrating macrophages was shown to initiate inhibitory
immune pathways mediated by MEK-ERK signaling (110).
Moreover, siglec-binding to sTn-expressing mucins, led to the
maturation of DCs and DC-mediated induction of FOXP3+
Treg cells and reduced INFγ-producing T cells (111, 112). A
recent study also demonstrates that siglec-9 expressed by CD8+
tumor infiltrating lymphocytes (TILs) in non-small cell lung
cancer (NSCLC) patients was associated with reduced survival.
Accordingly, siglec-9 polymorphisms were associated with the
risk of developing lung and colorectal cancer. Additionally, the
characterization of siglec-9+ CD8+ TILs revealed that these cells
concomitantly express several inhibitory receptors, including
PD-1, TIM-3, Lag3, and others. In addition, the same study
further reveals that lack of sialic acid-containing glycans in
tumor cells led to a delay of tumor growth and an increased
infiltration of CD3+ and CD8+ T cells (113).
Another important GBP that have been pointed out as
a crucial checkpoint in T cell viability and activity are
galectins. Galectin-1, 3, and 9 were predominantly described
in T cell immunosuppression. Galectin-1, was demonstrated
to be expressed by tolerogenic DCs (75) and CD4+CD25+
T cells (114), triggering T cell apoptosis through binding to
N-glycans and O-glycans on CD45, CD43, and CD7 or by
sensitizing resting T cells to FAS-induced death (115, 116).
The TH1 and TH17 activated cells are susceptible to galectin-
1-induced cell death once these cells express the repertoire
of glycans required for galectin-1 binding, while TH2 cells
are protected via α2,6-sialylation on cell surface glycoproteins,
which was described to preclude galectin-1 recognition and
binding (76). In addition, several tumors have the capacity
to secrete galectin-1 in order to promote immunosuppression,
through a mechanism that involves a bias toward a TH2
cytokine profile and activation of tolerogenic circuits mediated
by IL-27-producing DCs and IL-10-producing type 1 Treg cells
(117). On other hand, galectin-3 has an ambiguous role in
T cell viability: when it is localized at intracellular level, this
protein presents a protective role through a cell death inhibition
pathway that involves B-cell lymphoma 2 (Bcl-2) (118), whereas
extracellular galectin-3 induces cell death in activated T cells,
by binding to glycosylated receptors of T cells through a
distinct way than galectin-1 (115). Moreover, galectin-3 has
the capacity to bind to N-glycans on CTLA-4 prolonging the
inhibitory signals (119), as well as to Lag-3 on the surface of
CD8+ T cells, suppressing its function (120). Finally, galectin-9
abrogates TH1, TH17, and CD8+ T cells through glycosylation-
dependent binding to Tim-3 (121–123), whereas may regulate
pro-inflammatory cytokine production by binding with other
receptors (124).
Altogether, these findings support the relevance of glycans
on T cells-mediated immunosuppressive/tolerogenic pathways
which have relevant implications in tumor progression. Targeting
the abnormal glycosylation pattern of cancer cells constitutes a
promising strategy to instruct an effective anti-tumor immune
response, an issue that needs to be further explored.
GLYCANS AS METABOLIC REGULATORS
OF T CELL FUNCTION
The impact of glycosylation on T cell development and functions
is enormous, as revealed by the critical roles of glycans in
the development and progression of major diseases such as
auto-immunity and cancer, as described herein. In order to
accompany the bioenergetic and biosynthetic demands required
for T cell proliferation and activation, a shift in the T cell
metabolism is required. While naïve T cells are in a metabolic
quiescent state, mainly using oxidative phosphorylation to
maximize ATP production, T cells under clonal expansion or
under differentiation, reprogram their metabolic status to aerobic
glycolysis and glutaminolysis in order to increase the availability
of glycolytic precursors for the biosynthesis of nucleotides,
amino acids and lipids (125–127). During T cell activation,
the hexosamine biosynthetic pathway (HBP—a branch of
the glucose metabolism) is upregulated in order to generate
the nucleotide sugar-donor substrate UDP-GlcNAc, required
for N-glycosylation, O-GlcNAcylation, and glycosaminoglycans
production that are needed for a proper T cell function (128).
Mediators from the glycolytic pathway such as glucose (Glc),
glutamine (Gln), acetyl CoA are known to interfere with the
availability of the UDP-GlcNAc in the cell (129–131). Together
Glc and Gln were shown to increase UDP-GlcNAc in nutrient-
starved T cells. In the same setup, the supplementation of both
Glc and glucosamine (GlcN–a metabolite of the HBP) further
increased the UDP-GlcNAc cellular content, demonstrating
the sensitivity of the HBP to nutrients that enter directly
(GlcN) or through a precursor pathway (Glc in glycolysis)
(130). Despite the general use of the UDP-GlcNAc as a
substrate donor of HBP, there are some glycosyltransferases
that are more susceptible to nutrient changing than others,
such as the case of OGT (132). In fact, the supply with
Glc and Gln are crucial for protein O-GlcNAcylation, that
is important during T cell development, being associated
with T cell malignant transformation (23). Among the N-
acetylglucosaminyltransferases (GnTs) that participate in the
HBP, the less sensitive to nutrient changing (and thus substrate
availability) are GnT1, GnT2, and GnT3, due to lower Michaelis
Constant (Km) levels, meaning that these enzymes require low
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levels of the substrate to synthetize the specific glycans. In
contrast, GnT4 and GnT5 present higher Km and therefore their
activity is highly dependent on the availability of the UDP-
GlcNAc substrate (119, 133). Therefore, these two enzymes
are sensitive to alterations in glucose and HBP metabolism
(as the GlcN or N-acetyl glucosamine–GlcNAc) (62), which
ultimately will interfere in the N-glycan branching biosynthesis
on T cells with impact in their activity, as detailed in section
“Glycans in the regulation of T cell activity and functions” (60).
In fact, supplementation with Glc, Gln, and GlcNAc increases
branching N-glycans on Jurkat cells and resting T cells from
mice (85, 119, 130). Moreover, CD4+ T cells fromMGAT5+/+ or
MGAT5+/−− mice supplemented with oral GlcNAc also results
in up to 40% increase of branchingN-glycans, detected by L-PHA
(130). This enhancement of branching N-glycosylation upon
GlcNAc supplementation was shown to functionally impact on
T cells activity by reducing T cell activation, decreasing TH1
differentiation, and increasing retention of the growth inhibitory
receptor CTLA-4 at T cell surface (85, 130).
Importantly, evidences suggest that the glycolysis and
glutaminolysis compete with HBP pathway for the same
metabolites. Recently, Araujo et al showed that, during
TH17 differentiation the existence of common mediators
shared between HBP, glycolysis (fructose-6-phosphate) and
glutaminolysis (Gln) results in a starvation of the HBP
mediators, translated in a reduction of N-glycan branching
due to the limitation on the UDP-GlcNAc availability (53).
Fueling HBP with GlcNAc switched the cell fate from TH17 to
iTreg differentiation, through stimulation of IL2-Rα signaling
(53). This interplay between metabolic pathways was further
demonstrated by the increase on Glc, Gln, fatty-acids uptake,
and lipid storage upon stimulation of the HBP with GlcNAc
supplementation, suggesting a reprogramming of the cellular
metabolism upon GlcNAc flux (53, 134).
The impact of glycans as metabolic regulators of T cells
is also testified by its effects in ex vivo and in vivo models
of autoimmune diseases. The metabolic supplementation with
GlcNAc in ex vivo human colonic T cells from IBD patients
resulted in an enhancement of the branching N-glycosylation
pathway that was accompanied by a significant reduction of
T cell proliferation, supression of TH1/TH17 immune response
(through decreased production of IFN-γ and IL-17A pro-
inflammatory cytokines) and decreased TCR signaling (60).
Accordingly, the GlcNAc supplementation of mice models with
auto-immune diseases such as EAE, TID, and IBD results in
inhibition of TH1, TH17 immune response concomitantly with
a significant improvement of the clinical symptoms (60, 85).
Treatment with GlcNAc after disease onset also demonstrate
inhibitory effects on the development of the EAE, by reducing the
secretion of INF-γ, TNF-α, IL-17, and IL-22 (85). Interestingly, a
dual role of GlcN (the precursor of GlcNAc) on the progression
of autoimmune disorders was shown, by demonstrating its
impact in preventing TH1-mediated Type I diabetes (through the
reduction of IFN-γ producing CD4+ T cells), but also the GlcN
effects in exacerbating TH1/TH17–mediated EAE symptoms
(trough stimulation of TH17 response) (135). In contrast, another
study showed that GlcN suppresses acute EAE through the
blockage of TH1 and induction of TH2 response (136). GlcN
supplementation was further shown to mediate T cell activation
by decreasing the N-glycosylation of CD25 (IL-2Rα) from CD4+
T cell (135). This down-regulation of N-glycosylation might be
explained by the competition between GlcN and Glc for the same
glucose transporter which might impact in the reduction of the
GlcNAc concentration.
Altogether, alterations on the glucose metabolism and
partially changes in the metabolic flux of HBP have a
direct impact on T cells N-glycosylation profile with major
consequences in their function and activity. Ultimately, the
modulation of the HBP constitutes an important metabolic
target able to control both autoreactive and immunosuppressive
responses known to occur, respectively, in autoimmunity and
cancer.
CONCLUDING REMARKS
The contribution of the glycome as a major regulator of the
immune system is clear. Glycans actively participate in the
cellular and molecular mechanisms underlying the genesis of the
loss of immunological tolerance associated with (auto)immunity,
from one hand, participating also in the creation of tolerogenic
pathways associated with cancer progression, from the other.
The importance of glycans in immune response spans from its
role in the modulation the T cell development; their importance
as a source of glycoantigens presentation; as well as their
role as fine tuners of T cell response. In this context, glycans
can exert a dual role, acting either as immune inhibitory
checkpoints or as immune stimulatory signals. Understanding
in depth the influence of glycans in the immune regulatory
circuits that mediate the pathophysiology of autoimmunity and
cancer will generate a platform with extraordinary potential to
illuminate the identification of novel biomarkers and targets for
the development of efficient immunomodulatory strategies with
applications in the clinical setting.
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